ROIV · Roivant Sciences Ltd. · Executive Compensation
$39.57
+0.04 (+0.10%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q2 2027 earnings call transcript
Market Cap
$28.64B
Shares
724.56M
Volume · Nov 16
1.73M
Avg daily vol (3M)
8.07M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Frank Torti | President and Vant Chair | $123,300,566 |
| Eric Venker | President and Immunovant CEO | $24,400,210 |
| Richard Pulik | Chief Financial Officer | $4,190,602 |
| Matthew Gline | Chief Executive Officer | $3,096,190 |
| Mayukh Sukhatme | President and Chief Investment Officer | $1,276,655 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mayukh Sukhatme | President and Chief Investment Officer | $251,858,764 |
| Matthew Gline | Chief Executive Officer | $163,293,744 |
| Eric Venker | President and Immunovant CEO | $11,807,422 |
| Rakhi Kumar | Former Chief Accounting Officer | $4,693,938 |
| Richard Pulik | Chief Financial Officer | $4,127,151 |
| Jennifer Humes | Chief Accounting Officer | $2,382,956 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Richard Pulik | Chief Financial Officer | $5,149,434 |
| Rakhi Kumar | Former Chief Accounting Officer | $4,331,159 |
| Matthew Gline | Chief Executive Officer | $738,189 |
| Eric Venker | President and Immunovant CEO | $632,420 |
| Mayukh Sukhatme | President and Chief Investment Officer | $574,560 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Matthew Gline | Chief Executive Officer | $48,978,825 |
| Mayukh Sukhatme | President and Chief Investment Officer | $48,925,582 |
| Eric Venker | President and Immunovant CEO | $48,487,966 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Matthew Gline | Chief Executive Officer | $30,460,032 |
| Eric Venker | M.D., Pharm.D. President and Chief Operating Officer | $24,308,300 |
| Mayukh Sukhatme | President and Chief Investment Officer | $17,488,425 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Eric Venker | M.D., Pharm.D. President and Chief Operating Officer | $10,296,550 |
| Matthew Gline | Chief Executive Officer | $8,310,550 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Jennifer Humes | Principal Accounting Officer and Chief Accounting Officer of RSI | Appointed | 2025-02-21 |
| Rakhi Kumar | Principal Accounting Officer of Roivant Sciences Ltd. and Chief Accounting Officer of Roivant Sciences, Inc. | Resigned | 2025-02-21 |
| Hiroshi Nomura | Class III director | Resigned | 2023-08-04 |
| Meghan M. FitzGerald, DrPH | Class II director | Appointed | 2023-03-16 |
| Vivek Ramaswamy | Class II director | Resigned | 2023-02-21 |
| Dr. Andrew Lo | Class II director | Resigned | 2022-11-23 |
| Hiroshi Nomura | Class III director | Appointed | 2022-09-21 |
| Masayo Tada | director | Resigned | 2022-09-21 |
Leadership
- Eric Venker CEO, COO
- Matthew Gline CEO, Board Member
- Richard Pulik CFO
- Jennifer Humes Chief Accounting Officer
- Daniel Gold Board Member
- Hiroshi Nomura Board Member
- Ilan Oren Board Member
- James C. Momtazee Board Member
- Keith Manchester Board Member
- Mayukh Sukhatme Board Member
- Meghan FitzGerald Board Member
- Meghan M. FitzGerald, DrPH Board Member
- Melissa Epperly Board Member
Key facts
CIK
1635088
CUSIP
G76279101
13F (30d)
387 filings
351 filers
Visit website
Investor relations